-
Cerevel Therapeutics Holdings, Inc. is a
biotechnology and
pharmaceuticals company focused on the
development of
novel therapies for
mental and neurological...
-
agonist for the
treatment of Parkinson's disease.,
under development by
Cerevel Therapeutics who
acquired Tavapadon from
Pfizer in 2018. It acts as a selective...
-
Publicly Listed Leader in
Neuroscience Drug
Development -
Cerevel Therapeutics". www.
cerevel.com. July 30, 2020.
Retrieved March 11, 2024. "Perceptive...
-
treatment of both
schizophrenia and Alzheimer's
disease psychosis developed by
Cerevel Therapeutics. As of
February 2023, it is in
phase II of
clinical trial...
- 7
billion Cerevel sale". Reuters.
Retrieved January 2, 2024. Bunker, Ted (December 7, 2023). "Bain
Capital Banks M****ive
Return on
Cerevel Deal". The...
- well-tolerated.
Darigabat was
originated by
Pfizer and is
under development by
Cerevel Therapeutics and Pfizer. As of
January 2023, it is in
phase 2 clinical...
- dementia-related apathy. It was
originated by
Pfizer and is
under development by
Cerevel Therapeutics. CVL-871 acts as a
selective partial agonist of the dopamine...
-
taken by mouth. It was
originated by
Pfizer and is
under development by
Cerevel Therapeutics. As of
September 2022, CVL-354 is in
phase 1
clinical trials...
-
December 2023,
AbbVie announced that it will
acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an
attempt to
expand its drug pipeline...
- 2021
Nicholas F. Beim | CFR
board member, CFR.org "Tony Coles, M.D." bio,
Cerevel Therapeutics Rachel Evans,
Sabrina Willmer, Nick
Baker &
Brandon Kochkodin...
